Subscribe

Verde Science, Inc. (VRCI)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address 400 South Zang Boulevard 75208
Dallas, TX, US
CEO Harpreet Singh Sangha
IPO 2009-02-10
CIK 1390778 ISIN US92337L2034

Explore sections of this company profile

Description

Verde Science, Inc., a pharmaceutical research and development enterprise, is dedicated to advancing a diverse array of prescription medications derived from cannabinoids, intended for the treatment of numerous health conditions. The company, which initially operated as Rango Energy, Inc., officially transitioned to the name Verde Science, Inc. in May 2014. Established in 2007, the company maintains its operational headquarters in Dallas, Texas.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
359.6K
Beta
-6.16
Float Shares
20.72M
Free Float %
86.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.00% +0.00% +100.00% +100.00% +100.00% +100.00% +100.00% -99.43% -96.67% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-1,695.40
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
  • Revenue growth Biotechnology: +1.6%
  • EPS growth Biotechnology: +29.7%
    -175.7% Q3'15: +69.1% (vs Q3'14)
  • FCF margin FCF growth · Biotechnology: +16.2%
  • EBIT margin Biotechnology: +0.0%
  • ROIC Biotechnology: -16.1%
    Q3'15: +29.0% (vs Q3'14)
  • Share dilution Biotechnology: -3.4%
    +18.5% Q3'15: -6.7% (vs Q3'14)
  • Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.12× Q3'15: -0.27× (vs Q3'14)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (-6.16) × ERP
WACC = 0% × Ke + 100% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 0.00
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Owner Earnings

Owner's Earnings (history)

Owner's Earnings history not available.

Owner alignment
Owner's Earnings TTM
OE per share TTM
Owner's Yield
Maintenance CapEx ratio
Maint CapEx / Avg PPE

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2015-01-26 Sangha Harpreet Singh Director / Officer / 10% Owner P-Purchase A Common Stock 4,000,000 0.01 40.0K 4,042,857
2014-09-30 Sangha Harpreet Singh Director / Officer P-Purchase A Common Stock 1,000,000 0.01 12.0K 11,000,000

Executive team

Top executives
Shares Outstanding
23.87M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2018-06-28 8-K
2018-02-22 15-12G
2018-01-30 8-K
2017-12-06 8-K
2016-04-18 SC 13G
2015-12-15 10-Q
2015-09-18 8-K
2015-09-14 10-Q
2015-08-17 NT 10-Q
2015-07-31 8-K

Executive team

NameTitleCompensationGender
Harpreet Singh Sangha Chairman, Chief Executive Officer, President, Chief Financial Officer, Secretary & Treasurer 2.7K male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits